AbCellera

106 articles about AbCellera

• AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023

  11/16/2023

  AbCellera (Nasdaq: ABCL) today announced that management will present at the Piper Sandler 35th Annual Healthcare Conference in New York, New York on Thursday, November 30, 2023, at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time).

• AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

  11/3/2023

  AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) programs in two poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

• AbCellera Reports Q3 2023 Business Results

  11/2/2023

  AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2023.

• Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

  11/1/2023

  Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer.

• AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023

  10/31/2023

  AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023, at 4:30 p.m. Greenwich Mean Time (8:30 a.m. Pacific Time).

• AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023

  10/11/2023

  AbCellera (Nasdaq: ABCL) will announce its third quarter 2023 financial results on Thursday, November 2, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

• AbCellera Announces Two T-Cell Engager Presentations at SITC 2023

  9/27/2023

  AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1 to 5, 2023.

• AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron

  9/20/2023

  AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing multi-target collaboration with Regeneron (Nasdaq: REGN) to discover therapeutic antibodies for up to eight targets selected by Regeneron, increased from the original four.

• AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology

  9/13/2023

  AbCellera (Nasdaq:ABCL) announced today that it has entered into a strategic collaboration with Incyte (Nasdaq:INCY) to discover and develop therapeutic antibodies in oncology.

• AbCellera Reports Q2 2023 Business Results

  8/3/2023

  AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

• AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing

  7/24/2023

  AbCellera (Nasdaq: ABCL) announced that the United States Patent and Trademark Office’s (USPTO) Patent Trial and Appeal Board (PTAB) has denied a rehearing request in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera’s U.S. Patent No. 10,087,408 (the ‘408 Patent).

• AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023

  7/6/2023

  AbCellera will announce its second quarter 2023 financial results on Thursday, August 3, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time the same day.

• AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023

  5/29/2023

  AbCellera announced that executives from the Company will present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, California on Tuesday, June 13, 2023, at 1:20 p.m. Pacific Time.

• AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients

  5/24/2023

  AbCellera (Nasdaq: ABCL) today announced a CA$701 million co-investment with the Governments of Canada and British Columbia to build new capabilities and infrastructure to develop innovative antibody-based medicines and strengthen Canada’s leadership in clinical research, manufacturing, and drug development.

• AbCellera Reports Q1 2023 Business Results

  5/4/2023

  AbCellera announced financial results for the first quarter of 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

• AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023

  4/17/2023

  AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19, 2023.

• AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023

  4/11/2023

  AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, April 25, 2023, at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time).

• AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023

  4/6/2023

  AbCellera (Nasdaq: ABCL) will announce its first quarter 2023 financial results on Thursday, May 4, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

• AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease

  3/22/2023

  AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV).

• AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023

  3/14/2023

  AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19.